← Back to patent-cliff list
SIPI-6398
Tier C — Watch / tradeSIPI-6398
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DRD3, DRD2, 5-HT1A, 5-HT2A
Indications (approved)：Schizophrenia, Depressive disorder
Regional status
US
-
EU
-
China
Phase II
2023-12-27
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SIPI-6398?
Approved indications include: Schizophrenia, Depressive disorder.
When does the SIPI-6398 patent expire?
No public expiry year is available for SIPI-6398 yet; this page updates once verified.
How do I get a quote for SIPI-6398 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02